scholarly journals PERVASIVE HYPERMUTATION OF SUPER‐ENHANCER REGIONS DYSREGULATES ONCOGENE EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
E Bal ◽  
R Kumar ◽  
M Hadigo ◽  
A Holmes ◽  
K Basso ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Oncogene Expression ◽  
Large B Cell Lymphoma ◽  
Super Enhancer ◽  
Large B Cell

scholarly journals Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways

2019 ◽  
Vol 29 (1) ◽  
pp. 70-79
Author(s):  
Geffen Kleinstern ◽  
Huihuang Yan ◽  
Michelle A T Hildebrandt ◽  
Joseph Vijai ◽  
Sonja I Berndt ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Meta Analysis ◽  
B Cell Lymphoma ◽  
European Ancestry ◽  
Replication Studies ◽  
Large B Cell Lymphoma ◽  
Super Enhancer ◽  
Large B Cell ◽  
Original Gwas

Abstract We previously identified five single nucleotide polymorphisms (SNPs) at four susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in individuals of European ancestry through a large genome-wide association study (GWAS). To further elucidate genetic susceptibility to DLBCL, we sought to validate two loci at 3q13.33 and 3p24.1 that were suggestive in the original GWAS with additional genotyping. In the meta-analysis (5662 cases and 9237 controls) of the four original GWAS discovery scans and three replication studies, the 3q13.33 locus (rs9831894; minor allele frequency [MAF] = 0.40) was associated with DLBCL risk [odds ratio (OR) = 0.83, P = 3.62 × 10−13]. rs9831894 is in linkage disequilibrium (LD) with additional variants that are part of a super-enhancer that physically interacts with promoters of CD86 and ILDR1. In the meta-analysis (5510 cases and 12 817 controls) of the four GWAS discovery scans and four replication studies, the 3p24.1 locus (rs6773363; MAF = 0.45) was also associated with DLBCL risk (OR = 1.20, P = 2.31 × 10−12). This SNP is 29 426-bp upstream of the nearest gene EOMES and in LD with additional SNPs that are part of a highly lineage-specific and tumor-acquired super-enhancer that shows long-range interaction with AZI2 promoter. These loci provide additional evidence for the role of immune function in the etiology of DLBCL, the most common lymphoma subtype.

scholarly journals Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Cancer Cell ◽  
2014 ◽  
Vol 25 (4) ◽  
pp. 545-546 ◽  
Author(s):  
Bjoern Chapuy ◽  
Michael R. McKeown ◽  
Charles Y. Lin ◽  
Stefano Monti ◽  
Margaretha G.M. Roemer ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Super Enhancer ◽  
Large B Cell

scholarly journals Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Cancer Cell ◽  
2013 ◽  
Vol 24 (6) ◽  
pp. 777-790 ◽  
Author(s):  
Bjoern Chapuy ◽  
Michael R. McKeown ◽  
Charles Y. Lin ◽  
Stefano Monti ◽  
Margaretha G.M. Roemer ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Super Enhancer ◽  
Large B Cell

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document